Company recently completed Phase 3 RAMSES study and confirms safety profile of AR101 in peanut-allergic children and teens
BLA submission for AR101 on track for December 2018
Management to host analyst event on Wednesday, December 12th, in New York
[Read on via official release]
Source: US SEC
View full document:
EX-991_of_8-K_for_Aimmune_Therapeutics_Inc__8-K-11-08-2018
